The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Using MRD in myeloma clinical practice
Alessandro Gozzetti, MD, PhD, Azienda Ospedaliera Universitaria Senese, Siena, Italy, shares the main findings of his recent review of measurable residual disease (MRD) in multiple myeloma, published in the Journal of Personalized Medicine. With a focus on real-world clinical practice, Gozzetti reiterates that while MRD is not currently recommended for clinical therapeutic decisions, it can be beneficial to identify sustained responses in myeloma patients, and used as a test of the power of novel agents. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
